logo
  

Asbury Automotive Q1 Earnings Rise - Quick Facts

Asbury Automotive Group, Inc. (ABG) Tuesday reported that its first-quarter income from continuing operations rose to $35.9 million or $1.30 per share from last year's $31.5 million or $1.03 per share.

Net income for the first quarter was $35.9 million or $1.30 per share, compared to $31.4 million or $1.02 per share in the prior-year period

Total revenues in the quarter grew 14% to $1.5 billion. While both new vehicle retail revenues and used vehicle retail revenues were up 14 percent, Finance and insurance revenues grew 15 percent. Parts and service revenues were up 11 percent.

Analysts polled by Thomson Reuters expected the company to earn $1.18 per share, on revenues of $1.49 billion, for the quarter.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Shares of Siemens Energy AG were gaining more than 12 percent in German trading after the company on Wednesday raised its outlook for fiscal 2024 after reporting a profit in its second quarter, compared to last year's loss, amid positive market environment. Meanwhile, second-quarter orders were lower than last year, and the company maintained annual earnings forecast. AstraZeneca, a major provider of Covid-19 vaccines across the world mainly during the initial pandemic period, has initiated a process to withdraw its Vaxzevria COVID-19 vaccine worldwide, citing weak demand and the surplus availability of new vaccines. Meanwhile, AstraZeneca reportedly had admitted recently in court documents that the vaccine could cause side-effects such as blood clots... iPhone maker Apple is said to be working on designing and producing its own Artificial Intelligence-powered chips to run AI software on servers at its data centers, according to a Wall Street Journal report on Tuesday. The company, known for its iPhones, iPads, and Macs, is reportedly working with Taiwan Semiconductor Manufacturing Co. or TSMC, on this project code named as "ACDC"

This week, we feature J&J’s Talc litigation closure,Emergent’s strategic changes for growth ,Pfizer’s breakthrough hemophilia B gene therapy approval,Novartis’s strategic Mariana Oncology Buyout, and Beyfortus Breakthrough RSV prevention.

View More Videos
RELATED NEWS
Follow RTT